Literature DB >> 14694347

Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha.

Thomas J Gould1, Scott P Bizily, Jan Tokarczyk, Michele P Kelly, Steven J Siegel, Stephen J Kanes, Ted Abel.   

Abstract

Schizophrenia is a complex disorder characterized by wide-ranging cognitive impairments, including deficits in learning as well as sensory gating. The causes of schizophrenia are unknown, but alterations in intracellular G-protein signaling pathways are among the molecular changes documented in patients with schizophrenia. Using the CaMKIIalpha promoter to drive expression in neurons within the forebrain, we have developed transgenic mice that express a constitutively active form of G(s)alpha (G(s)alpha(*)), the G protein that couples receptors such as the D(1) and D(5) dopamine receptors to adenylyl cyclase. We have also generated mice in which the CaMKIIalpha promoter drives expression of a dominant-negative form of protein kinase A, R(AB). Here, we examine startle responses and prepulse inhibition of the startle reflex (PPI) in these G(s)alpha(*) and R(AB) transgenic mice. G(s)alpha(*) transgenic mice exhibited selective deficits in PPI, without exhibiting alterations in the startle response, whereas no deficit in startle or PPI was found in the R(AB) transgenic mice. Thus, overstimulation of the cAMP/PKA pathway disrupts PPI, but the cAMP/PKA pathway may not be essential for sensorimotor gating. G(s)alpha(*) transgenic mice may provide an animal model of certain endophenotypes of schizophrenia, because of the similarities between them and patients with schizophrenia in G-protein function, hippocampus-dependent learning, and sensorimotor gating.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14694347      PMCID: PMC3348581          DOI: 10.1038/sj.npp.1300309

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  62 in total

1.  Characterization of the disruptions of prepulse inhibition and habituation of startle induced by alpha-ethyltryptamine.

Authors:  D L Martinez; M A Geyer
Journal:  Neuropsychopharmacology       Date:  1997-03       Impact factor: 7.853

2.  P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis.

Authors:  B A Clementz; M A Geyer; D L Braff
Journal:  Biol Psychiatry       Date:  1997-05-15       Impact factor: 13.382

3.  Regulation of transcription by cyclic AMP-dependent protein kinase.

Authors:  P L Mellon; C H Clegg; L A Correll; G S McKnight
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

4.  Differential performance of acute and chronic schizophrenics in a latent inhibition task.

Authors:  I Baruch; D R Hemsley; J A Gray
Journal:  J Nerv Ment Dis       Date:  1988-10       Impact factor: 2.254

5.  Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies.

Authors:  Neal R Swerdlow; Angela Eastvold; Blythe Karban; Yvonne Ploum; Nora Stephany; Mark A Geyer; Kristin Cadenhead; Pamela P Auerbach
Journal:  Psychopharmacology (Berl)       Date:  2002-03-23       Impact factor: 4.530

Review 6.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

7.  The 3'-untranslated region of CaMKII alpha is a cis-acting signal for the localization and translation of mRNA in dendrites.

Authors:  M Mayford; D Baranes; K Podsypanina; E R Kandel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

8.  A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia.

Authors:  R Y Peng; R S Mansbach; D L Braff; M A Geyer
Journal:  Neuropsychopharmacology       Date:  1990-06       Impact factor: 7.853

9.  Nerve growth factor-induced neuronal differentiation after dominant repression of both type I and type II cAMP-dependent protein kinase activities.

Authors:  D D Ginty; D Glowacka; C DeFranco; J A Wagner
Journal:  J Biol Chem       Date:  1991-08-15       Impact factor: 5.157

10.  5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex.

Authors:  G C Rigdon; J K Weatherspoon
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

View more
  17 in total

1.  Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits.

Authors:  Kayla L Metzger; Jody M Shoemaker; Jonathan B Kahn; Christina R Maxwell; Yuling Liang; Jan Tokarczyk; Stephen J Kanes; Meredith Hans; Anthony M Lowman; Nily Dan; Karen I Winey; Neal R Swerdlow; Steven J Siegel
Journal:  Psychopharmacology (Berl)       Date:  2006-11-21       Impact factor: 4.530

2.  Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients.

Authors:  C R Maxwell; Y Liang; M P Kelly; S J Kanes; T Abel; S J Siegel
Journal:  Neuroscience       Date:  2006-06-05       Impact factor: 3.590

3.  Activation of a nitric-oxide-sensitive cAMP pathway with phencyclidine: elevated hippocampal cAMP levels are temporally associated with deficits in prepulse inhibition.

Authors:  Daniel Klamer; Erik Pålsson; Kim Fejgin; Jianhua Zhang; Jörgen A Engel; Lennart Svensson
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

4.  Phenylthiocarbamide (PTC) perception in patients with schizophrenia and first-degree family members: relationship to clinical symptomatology and psychophysical olfactory performance.

Authors:  Paul J Moberg; Colleen McGue; Stephen J Kanes; David R Roalf; Catherine C Balderston; Raquel E Gur; Christian G Kohler; Bruce I Turetsky
Journal:  Schizophr Res       Date:  2007-01-08       Impact factor: 4.939

5.  In vitro and in vivo demonstration of risperidone implants in mice.

Authors:  C Rabin; Y Liang; R S Ehrlichman; A Budhian; K L Metzger; C Majewski-Tiedeken; K I Winey; S J Siegel
Journal:  Schizophr Res       Date:  2007-08-31       Impact factor: 4.939

Review 6.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

7.  Chronically increased Gsalpha signaling disrupts associative and spatial learning.

Authors:  Rusiko Bourtchouladze; Susan L Patterson; Michele P Kelly; Arati Kreibich; Eric R Kandel; Ted Abel
Journal:  Learn Mem       Date:  2006 Nov-Dec       Impact factor: 2.460

8.  Possible role of the dopamine D1 receptor in the sensorimotor gating deficits induced by high-fat diet.

Authors:  Chisato Wakabayashi; Tadahiro Numakawa; Yoshiko Ooshima; Kotaro Hattori; Hiroshi Kunugi
Journal:  Psychopharmacology (Berl)       Date:  2015-09-11       Impact factor: 4.530

Review 9.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

10.  Behavioral and neurochemical alterations in mice lacking the RNA-binding protein translin.

Authors:  Joel M Stein; Wayland Bergman; Yanshan Fang; Lakesha Davison; Colleen Brensinger; Michael B Robinson; Norman B Hecht; Ted Abel
Journal:  J Neurosci       Date:  2006-02-22       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.